Phase One Sino-U.S. Trade Agreement and the Pharmaceutical Industry
On 16 January 2020, China and the United States signed the Economic and Trade Agreement between the Government of the People’s Republic of China and the Government of the United States of America (the Phase One Trade Agreement). The Phase One Trade Agreement includes a chapter on intellectual property aimed at resolving a wide range of key issues relating to intellectual property protection and enforcement, including, among other things, patents, pharmaceutical-related intellectual property and trade secrets. If properly performed and implemented through domestic legislation, the Phase One Trade Agreement would likely transform and modernise China’s patent system for the benefit of both the innovative pharmaceutical industry and the population it serves in China.
- Economic and Trade Agreement between the Government of the United States of America an the Government of the People’s Republic of China ( Full version)
- Trade Agreement (Fact Sheet)
- Trade Agreement: Chapter on IP (Fact sheet)